Migalastat Hydrochloride
- TRADE NAME: Galafold (Amicus Therapeutics US Inc)
- INDICATIONS: indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and is an amenable galactosidase alpha gene (GLA) variant.
- CLASS: Alpha-galactosidase A (alpha-Gal A) pharmacological chaperone
- HALF-LIFE: ~4 hours
FDA APPROVAL DATE: 08/10/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
available data are not sufficient to assess drug associated risks
Please login to see the rest of this drug profile
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric